Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | HRH2 | P25021 | 4/20 | 0.41 |
| ▸ | HRH1 | P35367 | 4/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028285 | 0.90 | CYP19A1 (0.38) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL2963106 | 0.89 | KCNH2 (0.41) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL5965627 | 0.87 | HRH2 (0.37) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL6095376 | 0.86 | HRH3 (0.46) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL7242820 | 0.86 | HRH3 (0.40) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL6095400 | 0.85 | HTR7 (0.42) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL6095242 | 0.84 | HRH3 (0.59) | HRH3HRH2HRH1HTR7CYP19A1 | |
| SCHEMBL6093051 | 0.83 | HRH1 (0.49) | HRH3HRH2HRH1HTR7ALDH1A1 | |
| SCHEMBL6095695 | 0.83 | HRH3 (0.43) | HRH3HRH2HRH1HTR7TMEM97 | |
| SCHEMBL6094465 | 0.83 | HRH3 (0.56) | HRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | HRH3 3033/4885HRH2 2122/4885HRH1 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.